Advancements of investigational agents for cancer cachexia: what clinical progress have we seen in the last 5 years?
INTRODUCTION
Cancer cachexia is a multifactorial syndrome affecting up to 80% of advanced cancer patients, associated with poor quality of life, increased cancer-treatment toxicity, and reduced survival. Despite its clinical burden, no FDA- or EMA-approved pharmacologic therapies currently exist.
AREAS COVERED
This review...
